The AMR Centre, a body with public and private investors leading the UK’s response to the global health threat posed by antimicrobial resistance, has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.
The package totals £2.3m and is led by an investment from LifeArc, one of the UK’s foremost medical research charities. Other backers include Bruntwood SciTech, MGL, and the Greater Manchester and Cheshire Life Sciences Fund.
Based at Alderley Park, Cheshire, the AMR Centre is focused on accelerating the development of…
Developers of pioneering prognostic tools recognised for its innovative product development and contribution to life science discovery
Cambridge, UK, 21 April 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, are delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.
Held annually, The Business Weekly awards reflect the successful and fast-paced nature of the innovation cluster in the East of England. World-class and…
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.
Arecor’s AT247, is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. Prandial insulin is used…
Babraham Research Campus is offering companies seeking funding the opportunity to present at its 10th investor conference
Babraham 18th March 2018: The Babraham Investor Conference (BIC) is back to bring together like-minded investors focussed on early-stage and scale-up life science and med-tech opportunities.
And now, companies seeking funding of between £250K to £20M have the opportunity to pitch to an audience of potential investors on 15 May at the Babraham Research Campus, Cambridge.
Presenting slots are 15 minutes each, including Q&A. There is also ample time for networking…
Aigenpulse Ltd., (Aigenpulse), a big data technology company which specialises in structuring, integrating and deriving meaning from large, disparate data assets in the life sciences sector, is continuing to strengthen its management team with the addition of Head of Delivery and Head of DevOps.
Michal Wozny has been brought in as Aigenpulse’s Head of Delivery and is responsible for managing internal and customer projects from inception through to delivery. In order to ensure quality assured projects are delivered on budget and on time, Michal uses PRINCE2 and AGILE methodologies, as this…
LOUGHBOROUGH, England (March 13, 2019) – Thermo Fisher Scientific, the world leader in serving science, recently announced the winners of the Fisher Scientific Channel Supplier Awards during its annual Fisher Scientific European Sales Conference held in Poland.
From March 4-7, 2019, almost 750 delegates attended the Fisher Scientific European Sales Conference at the Gołębiewski Hotel, Karpacz, Poland. This was the eighth event of its kind, bringing together delegates from 21 different countries.
The event, themed Gaining Advantage, included an exhibition showcase with 62 booths featuring…
SAMPLE MANAGEMENT
Due to its flexibility to be configured to address a wide spectrum of data challenges within the research environment, LabKey Server has long been assumed to be a LIMS system. It's true, LabKey can be used as fundamental sample management / tracking / processing tool. Things are about to get even more interesting !
Sample management is an area of major investment and feature expansion for 2019. Building on LabKey Server’s existing foundation of sample management features, the LabKey team is working to develop a suite of new capabilities to support the registration and…
Evaluation by the Diagnostic Assessment Programme provides independent support and validation of PredictImmune’s first product addressing IBD
Cambridge, UK, 12 March 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the formal entry of its first product, PredictSURE IBD™, into NICE’s Diagnostic Assessment Programme (DAP).
The DAP evaluates new, cutting-edge medical diagnostic technologies, producing guidance to help people working in the NHS make efficient, cost-effective and…
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.
Susan has significant experience working with fast-growing life science companies and of the public markets. She was previously Chief Financial Officer and an executive director of AIM listed, IXICO plc (AIM: IXI), a neuroimaging and digital…
Large, real-world, prospective study shows Inivata’s liquid biopsy test is able to provide molecular profile when tissue is unavailable and guide personalized treatment
High levels of concordance, sensitivity and specificity validate InVision in advanced NSCLC
Research Triangle Park, NC and Cambridge, UK, March 7, 2019 — Inivata, a leader in liquid biopsy, today announces the publication of results of a clinical validation and real-world utility study of its InVision® amplicon-based technology for use in advanced non-small cell lung cancer (NSCLC). The study was conducted in collaboration…